Rev Esp Quimioter 2018; 31(2): 105-109

Use of hepatitis B AS04C adjuvanted vaccine in HIV patients

MARÍA FERNÁNDEZ-PRADA, OMAR DARÍO RODRÍGUEZ-FONSECA, ANAHY MARÍA BRANDY-GARCÍA, PAULA ALONSO-PENANES, ISMAEL HUERTA-GONZÁLEZ, FEDERICO FERNÁNDEZ-NOVAL

Introduction. Co-infection with hepatitis B virus (HBV) in patients with human immunodeficiency virus (HIV) increases associated morbidity and mortality. Vaccination against HBV has been shown to be the most effective method to prevent this situation. Standard vaccination schemes used in this population do not appear to be effective enough. The objective is to identify the response rate following the use of AS04C-adjuvanted hepatitis B vaccine in HIV patients as well as the possible associated adverse reactions.
Methods. An observational, analytical study with a retrospective cohort of HIV positive patients discharged in 2016 from the Vaccines Unit of a Preventive Medicine and Public Health Service. Patients with antiHBs (-), antiHBcActot (-) and HBsAg (-) at baseline were included, none of them had received prior HBV vaccination. HBV adjuvanted vaccine was used in a 4-dose regimen (0-1-2-6 months). When antiHBs was <10 IU/mL after primovaccination, two additional doses of the same vaccine were applied with an interval of 30 days.
Results. A total of 39 patients were included. Of them, 74.4% were men. The mean age was 47.26 years. The response rate after primary vaccination was higher than 92% and up to 100% with the two subsequent doses. No adverse reactions were reported.
Conclusion. The administration of AS04C-adjuvanted hepatitis B vaccine in HIV patients showed a 100% response rate, showing an excellent safety profile.

Rev Esp Quimioter 2018; 31(2): 105-109 [Texto completo PDF]